{
    "nct_id": "NCT05920356",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2023-06-27",
    "study_start_date": "2023-11-16",
    "study_completion_date": null,
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: Sotorasib"
            },
            {
                "drug_name": "Drug: Pembrolizumab"
            }
        ]
    },
    "long_title": "A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)",
    "last_updated": "2025-08-28",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE3",
    "principal_investigator": "NA, Victor LEE, Wendy CHAN",
    "principal_investigator_institution": "Amgen, HKU",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [
        "20190341",
        "GSUS-598-6168",
        "UW 23-407"
    ],
    "protocol_no": "",
    "protocol_target_accrual": 750,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Inclusion Criteria:",
        "* Histologically or cytologically confirmed diagnosis of nonsquamous stage IV or advanced Stage IIIB or IIIC NSCLC with KRAS p. G12C mutation and negative for PD-L1 expression by central testing or local laboratory testing confirmed through central testing",
        "* No history of systemic anticancer therapy in metastatic/non-curable settings",
        "* Eastern Cooperative Oncology Group (ECOG) \u2264 1",
        "Exclude - Exclusion Criteria:",
        "Exclude - * Mixed histology NSCLC with either small-cell or large-cell neuroendocrine cell component or predominant squamous cell histology",
        "Exclude - * Participants with tumors known to harbor molecular alterations for which targeted therapy is locally approved as a front-line therapy",
        "Exclude - * Symptomatic (treated or untreated) brain metastases",
        "Exclude - * Gastrointestinal (GI) tract disease causing the inability to take oral medication",
        "Exclude - * Myocardial infarction within 6 months of randomization, unstable arrhythmias, or unstable angina",
        "Exclude - * Prior therapy with a KRAS G12C inhibitor"
    ],
    "short_title": "A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "Amgen",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "Sotorasib combined with carboplatin and pemetrexed",
                        "arm_internal_id": 0,
                        "arm_description": "Sotorasib administered in combination with carboplatin and pemetrexed.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Sotorasib",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Pembrolizumab combined with carboplatin and pemetrexed",
                        "arm_internal_id": 1,
                        "arm_description": "Pembrolizumab administered in combination with carboplatin and pemetrexed.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Pembrolizumab",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "and": [
                            {
                                "and": [
                                    {
                                        "or": [
                                            {
                                                "clinical": {
                                                    "oncotree_primary_diagnosis": "Non-Small Cell Lung Cancer"
                                                }
                                            },
                                            {
                                                "clinical": {
                                                    "oncotree_primary_diagnosis": "Sarcomatoid Carcinoma of the Lung"
                                                }
                                            }
                                        ]
                                    },
                                    {
                                        "clinical": {
                                            "age_numerical": ">=18",
                                            "pdl1_status": "Low",
                                            "disease_status": [
                                                "Metastatic",
                                                "Advanced"
                                            ]
                                        }
                                    }
                                ]
                            },
                            {
                                "and": [
                                    {
                                        "or": [
                                            {
                                                "genomic": {
                                                    "hugo_symbol": "KRAS",
                                                    "variant_category": "Mutation"
                                                }
                                            }
                                        ]
                                   }
                                ]
                            }
                        ]
                    }
                ]
            }
        ]
    }
}
